Rocket Lab's 95% Upside Is a Bet on a Rocket That Has Never Flown

The "95% upside" prediction doing the rounds for Rocket Lab — roughly $62 up to $121 — is not really a forecast about a company. It is a forecast about one rocket that has never flown and has already missed more than one promised deadline. The author of the target says so himself: he attaches only about 50% confidence to it, because everything hangs on Neutron's first flight and a satellite acquisition closing. That admission is the most useful thing in the whole call, because it tells you that the price is already living inside the optimistic half of the distribution.

Here is what the stock asks you to believe in. At about $62, Rocket Lab carries a market capitalization near $38 billion on negative earnings and sells for roughly 49 times trailing revenue. The shares are down about 20% this month even after a quarter that beat expectations, and they trade roughly 58% below the $151 they touched within the past year. This is a stock that already ran up on a story and is now deflating on delivery. The bulls will tell you the pullback is the entry. It may be. But first, know which story you are buying.

The business is real; the 95% is not the business

None of this is a knock on the underlying company, which is genuinely strong. Second-quarter revenue was a record $234 million, up 62% year over year, and the product line — the satellites and components Rocket Lab builds and sells — rose 96%. Backlog hit a record $2.36 billion, up 137%, spanning more than 90 launches. Third-quarter revenue is guided to $250 million to $265 million, above the roughly $238.5 million Wall Street had expected. The defense pipeline is real too: a $397 million Space Force contract, a role in the Golden Dome missile-defense program, and an announced acquisition of satellite operator Iridium. Reflecting all of it, AInvest's aggregate signal labels the shares a Buy, and the average analyst target sits near $71 — roughly where the stock trades.

The trap is the distance between $71 and $121. Growth, backlog, and defense awards compound year after year; that is the baseline business, and it is good. But it does not by itself justify 49 times trailing sales for a company that still loses money. The step-change that does — the leap to $121, or even to the author's own "bear" case near $95 — comes from Neutron, the reusable medium-lift rocket built to go head-to-head with SpaceX's Falcon 9 at roughly $50 million a launch. Neutron is the variable that turns a well-run, fast-growing, unprofitable space firm into the reusability machine the multiple already assumes it will become.

The clock runs on one rocket

Now the part of the thesis that never makes it onto a target chart. Neutron's first flight has slipped before: a first-stage fuel tank ruptured in a pressure test in January, moving the debut from mid-2026 toward late 2026. The launch window is narrowing, and Rocket Lab's own filing acknowledges the first flight could slide into 2027. Management's own highest-risk item is the integrated static fire at the Virginia pad — lighting up a fully fueled vehicle for the first time — and the schedule is being traded off not against a single clean flight but against reaching "Flight Ten in the shortest time possible." Reuse, not one launch, is where the economics live. Every quarter of delay pushes both the first dollars of that reuse and the cash-flow turn the multiple is counting on further out.

That is why a Neutron slip is not a small downgrade here; it is a de-rating. When 49 times trailing sales is justified only by the re-rating Neutron is supposed to unlock, a delay does not just push timing out — it knocks the multiple down toward what the non-Neutron business alone supports. That underlying business is the same good company, but at a price that still starts in the forties on sales. So when a slip lands, the forced move is out of the rocket premium, not out of the business, and the shares fall even as revenue keeps growing.

Read the call the way its author wrote it

Treat the target for what it explicitly is: a roughly 50% bet on a pair of binary events. The falsifiable version runs on a single observable. If Rocket Lab books Neutron's debut in 2027, expect the stock to slide toward the low end of that published $95-to-$121 band before any leg higher — the backlog intact, the multiple doing the falling. Kill the whole framework only if the opposite happens: Neutron flies on schedule, shows reuse, and the shares still fail to re-rate. Then the market had already paid, and there was never a gap to exploit.

Until one of those two things shows up, keep straight what the "95% upside" genuinely is: the reward on the successful branch of one historically late rocket, attached to a good business you would own anyway, at nearly fifty times sales. The clock does not run on backlog growth. It runs on a launch date. Decide how you would answer if that date moves to 2027 before you decide the upside is yours.